Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Identification of factors that improve muscle function in boys with Duchenne muscular dystrophy (DMD) could lead to an improved quality of life. To establish a functional in vitro assay for muscle strength, mdx murine myoblasts, the genetic homologue of DMD, were tissue engineered in 96‐microwell plates into 3‐dimensional muscle constructs with parallel arrays of striated muscle fibers. When electrically stimulated, they generated tetanic forces measured with an automated motion tracking system. Thirty‐one compounds of interest as potential treatments for patients with DMD were tested at 3 to 6 concentrations. Eleven of the compounds (insulin‐like growth factor‐1, creat‐ine, β‐hydroxy‐β‐methylbutyrate, trichostatin A, lisino‐pril, and 6 from the glucocorticoid family) significantly increased tetanic force relative to placebo‐treated controls. The glucocorticoids methylprednisolone, deflazacort, and prednisone increased tetanic forces at low doses (EC 50 of 6, 19, and 56 nM, respectively), indicating a direct muscle mechanism by which they may be benefitting DMD patients. The tetanic force assay also identified beneficial compound interactions (arginine plus deflazacort and prednisone plus creatine) as well as deleterious interactions (prednisone plus creatine inhibited by pentoxifylline) of combinatorial therapies taken by some DMD patients. Since mdx muscle in vivo and DMD patients respond in a similar manner to many of these compounds, the in vitro assay will be a useful tool for the rapid identification of new potential treatments for muscle weakness in DMD and other muscle disorders.—Vandenburgh, H., Shansky, J., Benesch‐Lee, F., Skelly, K., Spinazzola, J.M., Saponjian, Y., Tseng, B.S. Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. FASEB J . 23, 3325–3334 (2009). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle
Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.009 · Cited by 683
Villalta, S. A., Nguyen, H. X., Deng, B., Gotoh, T., & Tidball, J. G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn376 · Cited by 512 · cited 1×
“They may also be deleterious in the in vivo environment in the presence of an immune system (51).”
BackgroundNissen, S. L., & Sharp, R. L. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00755.2002 · Cited by 258
Pharmacological strategies for muscular dystrophy
Khurana, T. S., & Davies, K. E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1085 · Cited by 225
Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy
Tarnopolsky, M. A., Mahoney, D. J., Vajsar, J., Rodriguez, C., Doherty, T. J., Roy, B. D., & Biggar, D. (2004) · Neurology · doi:10.1212/01.wnl.0000125178.18862.9d · Cited by 216 · cited 1×
“in vitro mdx mBAM assay: IGF-I (14), creatine (29),”
Method
Cited by
Engineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
Measuring cell-generated forces: a guide to the available tools
Polacheck, W. J., & Chen, C. S. (2016) · Nature Methods · doi:10.1038/nmeth.3834 · Cited by 489
Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
Design and formulation of functional pluripotent stem cell-derived cardiac microtissues
Thavandiran, N., Dubois, N., Mikryukov, A., Massé, S., Beca, B., Simmons, C. A., Deshpande, V. S., McGarry, J. P., Chen, C. S., Nanthakumar, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311120110 · Cited by 285
Chal, J., Al Tanoury, Z., Hestin, M., Gobert, B., Aivio, S., Hick, A., Cherrier, T., Nesmith, A. P., Parker, K. K., & Pourquié, O. (2016) · Nature Protocols · doi:10.1038/nprot.2016.110 · Cited by 299
Metadata
- Authors
- Vandenburgh, H., Shansky, J., Benesch-Lee, F., Skelly, K., Spinazzola, J. M., Saponjian, Y., & Tseng, B. S.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2009-06
- Volume
- 23
- Issue
- 10
- Pages
- 3325-3334
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2166257330
- Cited by
- 109
- References
- 6
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. https://app.cochat.ai/papers/10.1096/fj.09-134411
- The paper
- Vandenburgh, H., Shansky, J., Benesch-Lee, F., Skelly, K., Spinazzola, J. M., Saponjian, Y., & Tseng, B. S. (2009). Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. The FASEB Journal. https://doi.org/10.1096/fj.09-134411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.